Non-steroidal progesterone receptor modulators

Puwen Zhang, Andrew Fensome, Jay Wrobel, Richard C. Winneker, Zhiming Zhang
In: Expert Opinion on Therapeutic Patents · 2003 · vol. 13(12) , pp. 1839–1847 · doi:10.1517/13543776.13.12.1839 · W3142147566
article OA: closed CC0
View on OpenAlex View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-09 ⓘ

This review covers recent developments in non-steroidal progesterone receptor modulators, highlighting their potential as contraceptive agents and for treating gynecological conditions.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Progesterone (P4) plays an essential role in female reproduction and progesterone receptor (PR) agonists have been used in female contraceptives and in postmenopausal hormone therapy. Recent studies in women and non-human primates show that PR antagonists may also have potential as contraceptive agents and for the treatment of various gynaecological and obstetric diseases, including fibroids, endometriosis and, possibly, hormone-dependent cancers. Clinically available PR agonists and antagonists are steroidal compounds and often cause various side effects due to their functional interaction with other steroid receptors. Recently, numerous receptor-selective non-steroidal PR agonists and antagonists have emerged. This patent review will focus on the latest developments in these areas (since 2000).

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

References (43)

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
unpaywall
last seen: 2026-08-24T06:27:14.670421+00:00
License: CC0 · commercial use OK